Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

BACKGROUND: Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Tosoni, Alicia, Eoli, Marica, Lombardi, Giuseppe, Clavarezza, Matteo, Paccapelo, Alexandro, Bartolini, Stefania, Cirillo, Luigi, Agati, Raffaele, Franceschi, Enrico
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Clinical Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589683/
https://ncbi.nlm.nih.gov/pubmed/28903444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15735
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi